S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1891-1896

  Deichmann, Martin ^a   Benner, Axel ^a   Bock, Michael ^a   Jäckel, Andreas ^a   Uhl, Karen ^a   Waldmann, Volker ^a   Näher, Helmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL;

EID: 0033032641     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1891     Document Type: Article

References (27)

1. Moore BW: A soluble protein characteristic of the nerve system. Biochem Biophys Res Commun 19:739-744, 1965
2. Gaynor R, Irie R, Morton DL, et al: S100 protein in cultured human malignant melanomas. Nature 286:400-401, 1980
3. Carrel S, Rimoldi D: Melanoma-associated antigens. Eur J Cancer 29:1903-1907, 1993
4. Bosserhoff AK, Hein R, Bogdahn U, et al: Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein, MIA. J Biol Chem 271:490-495, 1996
5. Apfel R, Lottspeich F, Hoppe J, et al: Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res 2:327-336, 1993
6. Bogdahn U, Apfel R, Hahn M, et al: Autocrine tumor cell inhibiting activities from human malignant melanoma. Cancer Res 49:5358-5363, 1989
7. Fagnart OC, Sindic CJM, Laterre C: Particle counting immunoassay of S100 protein in serum: Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 34:1387-1391, 1988
8. Bosserhoff AK, Kaufmann M, Kaluza B, et al: Melanoma-inhibiting activity: A novel serum marker for progression of malignant melanoma. Cancer Res 57:3149-3153, 1997
9. Hein R, Bosserhof AK, Stolz W, et al: MIA serum levels as a detection and monitoring system of malignant melanoma. Arch Dermatol Res 289: A30, 1997 (abstr)
10. Guo HB, Stoffel-Wagner B, Bierwirth T, et al: Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31:924-928, 1995
11. Henze G, Dummer R, Joller-Jemelka HI, et al: Serum S100: A marker for disease monitoring in metastatic melanoma. Dermatology 194:208-212, 1997
12. Jäckel A, Deichmann M, Waldmann V, et al: S100β protein in serum, a tumor marker in malignant melanoma: Current state of knowledge and clinical experience. Hautarzt 50:250-256, 1999
13. American Joint Committee on Cancer: Manual for Staging of Cancer (ed 3). Philadelphia, PA, Lippincott. 1987, pp 143-148
14. Seregni E, Massaron S, Martinetti A, et al: S100 protein serum levels in cutaneous malignant melanoma. Oncol Rep 5:601-604, 1998
15. Abraha HD, Fuller LC, DuVivier AWP, et al: Serum S100 protein: A potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 137:381-385, 1997
16. von Schoultz E, Hansson LO, Djureen E, et al: Prognostic value of serum analyses of S100β protein in malignant melanoma. Melanoma Res 6:133-137, 1996
17. Coughlin SS, Trock B, Criqui MH, et al: The logistic modelling of sensitivity, specificity and predictive value of a diagnostic test. J Clin Epidemiol 45:1-7, 1991
18. Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics 38:1011-1016, 1982
19. Harrell FE: Predicting Outcomes, Applied Survival Analysis and Logistic Regression. Charlottesville, VA, University of Virginia, 1998
20. Nagelkerke NJD: A note on a general definition of the coefficient of determination. Biometrika 78:691-692, 1991
21. Kuhfeld WF: Algorithms for the PRINQUAL and TRANSREG procedures. SAS technical report R-108. Cary, NC, SAS Institute, 1990
22. Gabriel KR: The biplot graphical display of matrices with applications to principal component analysis. Biometrika 58:453-467, 1971
23. van Groningen JJM: Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res 55:6237-6243, 1995
24. Heimdal K, Hannisdal E, Gunderson S: Metastatic malignant melanoma. Eur J Cancer 25:1219-1223, 1989
25. Sirott MN, Bajorin DF, Wong GYN, et al: Prognostic factors in patients with metastatic malignant melanoma. Cancer 72:3091-3098, 1993
26. Buer J, Probst M, Franzke A, et al: Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 75:1373-1376, 1997
27. Dietz U, Sandell LJ: Cloning of a retinoid acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem 271:3311-3316, 1996